Drug · DIN 02496372
XOFLUZA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 15, 2026; first marketed January 15, 2026.
- Drug Identification Number (DIN)
- 02496372
- Company (DIN owner)
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Baloxavir marboxil J05AX25
- Class
- Human
- Record last updated
- February 9, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BALOXAVIR MARBOXIL | 40 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 19, 2020: NOC 23228New Drug Submission (NDS)
Other DINs named XOFLUZA
- DIN 02496364 · Marketed
- DIN 02524163 · Marketed